Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the 11 Best Short-Term Stocks to Invest in.

The company sees its Buy rating reiterated following promising results from its clinical trials, including the VERITAC-2 trial.

Headquartered in California, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for women’s cancers. Its lead product candidate, palazestrant (OP-1250), is an estrogen receptor (ER) antagonist and degrader being evaluated in clinical trials for breast cancer. The company also has another drug candidate, OP-3136, a KAT6 inhibitor, in Phase 1 clinical trials.

In its Q1 earnings report, released on May 13, 2025, the company announced that the OPERA-02 trial for palazestrant and ribociclib in breast cancer is on track for initiation in 2025. The OPERA-01 monotherapy trial also continues, with results expected in 2026. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has further promising results in clinical data for OP-3136 in multiple cancer types.

Additionally, the company’s trials on VERITAC-2 showed that the drug is more effective for metastatic breast cancer with ESR1 mutations, as it improves survival with a good safety profile. Following these developments, H.C. Wainwright reiterated the Buy rating on the stock while maintaining the price target of $28.00.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is showing a potential short-term rebound, gaining 7.19% this week despite a decline of 67.38% over the past year, attracting the interest of short-term investors.

While we acknowledge the potential of OLMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.